Alixia Analysis: $2M Raised
What is Alixia?
Alixia targets cancer drug resistance by studying tumor ecosystems and developing therapies that disrupt metabolic and inflammatory triggers in cancer cells.
Employees
2
Founded
2022
Revenue
$1M
Product Features & Capabilities
- tumor ecosystem disruptors, compounds targeting metabolic and inflammatory triggers, therapeutic portfolio addressing cancer, aging, neurodegeneration, inflammation, immune dysregulation
How much Alixia raised
1 - $1,825,445
July 23, 2024Lead Investor: Not specified
Who are the founders of Alixia
OM
Olof Mollstedt
Co-founder & Co-CEO
HC
Helen Chen, Ph.D.
Co-founder & Co-CEO
Investors
- Y Combinator
- IndieBio
- Eight Capital
- Endless Frontier Labs
- MCMA Ventures
- Gaingels
Market Focus
Alixia primarily focuses on the biotechnology and pharmaceutical industry, specifically targeting cancer treatment by addressing drug resistance and studying tumor interactions to develop therapeutic innovations.
Business Model
Focus on therapeutic innovations; revenue from funding and partnerships in cancer research.
Competitors Overview
Alixia operates in the cancer therapeutics market, focusing on addressing drug resistance through innovative therapies targeting the tumor ecosystem. Its main competitors include:
- ORIC Pharmaceuticals: This company develops therapies specifically aimed at overcoming cancer resistance, enhanc
See something that needs updating? Suggest edits to this profile.